Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued on Thursday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Up 1.6 %

NASDAQ EGRX opened at $0.65 on Thursday. The business has a 50 day simple moving average of $0.68 and a 200 day simple moving average of $2.57. Eagle Pharmaceuticals has a one year low of $0.00 and a one year high of $6.81.

Hedge Funds Weigh In On Eagle Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in EGRX. Mackenzie Financial Corp bought a new stake in shares of Eagle Pharmaceuticals during the second quarter valued at approximately $60,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Eagle Pharmaceuticals during the second quarter worth about $65,000. Fidelis Capital Partners LLC purchased a new position in shares of Eagle Pharmaceuticals in the 2nd quarter worth approximately $71,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Eagle Pharmaceuticals in the 2nd quarter worth about $76,000. Finally, Creative Planning purchased a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter worth approximately $59,000. Institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.